10-Q: Sotera Health Q2 Sees Revenue Growth Amidst EO Litigation

Sotera Health reported increased revenues and Adjusted EBITDA for Q2 2025, but net income declined due to significant Ethylene Oxide litigation settlements.

Summary

• Total net revenues increased by 6.4% to $294.3 million for Q2 2025 and by 4.6% to $548.9 million for H1 2025, driven by service revenue growth.
• Net income for Q2 2025 was $8.0 million, a 9.0% decrease from Q2 2024, and a net loss of $5.3 million for H1 2025, compared to a net income of $15.1 million in H1 2024.
• Adjusted EBITDA rose by 9.8% to $150.7 million for Q2 2025 and by 9.3% to $272.6 million for H1 2025, reflecting underlying operational improvements.
• The company incurred $34.0 million in Illinois EO litigation settlements in Q2 2025, contributing to a total of $64.9 million for H1 2025.
• Cash and cash equivalents increased to $332.4 million as of June 30, 2025, up from $277.2 million at December 31, 2024.

Sentiment

Score: 5

Explanation: The company shows strong underlying operational performance with revenue growth and increased Adjusted EBITDA across segments. However, significant legal settlements related to Ethylene Oxide litigation have led to a GAAP net loss for the six-month period, creating substantial financial uncertainty and ongoing legal expenses. The mixed results and persistent legal overhang balance out the positive operational trends.

Positives

• Total net revenues increased by 6.4% for the three months and 4.6% for the six months ended June 30, 2025, demonstrating continued top-line growth.
• Adjusted EBITDA grew by 9.8% for the three months and 9.3% for the six months ended June 30, 2025, indicating strong operational performance excluding non-recurring items.
• Sterigenics segment revenue increased by 10.5% for the quarter and 6.3% for the six months, driven by volume/mix and favorable pricing.
• Nordion segment revenue increased by 2.9% for the quarter and 14.9% for the six months, with strong volume/mix and pricing contributing to growth.
• Nelson Labs segment income margin improved significantly to 34.2% for the quarter and 32.9% for the six months, due to volume/mix improvements, lab optimization, and favorable pricing.
• Net cash provided by operating activities increased to $112.9 million for the six months ended June 30, 2025, up from $71.0 million in the prior year.
• The Revolving Credit Facility capacity increased to $600.0 million, with $585.8 million available as of June 30, 2025, enhancing liquidity.
• Amortization of intangible assets decreased by 39.7% for the quarter and 20.9% for the six months due to certain assets being fully amortized.
• The company was in compliance with all debt covenants as of June 30, 2025.

Negatives

• Net income decreased by 9.0% for the three months ended June 30, 2025, and the company reported a net loss of $5.3 million for the six months ended June 30, 2025, primarily due to significant litigation settlements.
• Product revenues decreased by 4.5% for the three months ended June 30, 2025, driven by lower Co-60 revenues due to timing of reactor harvest schedules.
• Selling, General and Administrative (SG&A) expenses increased by 13.7% for the quarter and 11.1% for the six months, largely due to increased litigation and professional services expenses related to EO sterilization facilities.
• The company incurred $34.0 million in Illinois EO litigation settlements in Q2 2025, contributing to a total of $64.9 million for H1 2025.
• Nelson Labs net revenues decreased by 3.3% for the quarter and 6.3% for the six months, primarily due to a decline in expert advisory services revenue.
• Foreign exchange resulted in a loss of $0.6 million for the quarter and $0.9 million for the six months, compared to gains in the prior year periods.

Risks

• Disruption in availability or supply of, or increases in price of, ethylene oxide (EO), Cobalt-60 (Co-60), or other direct materials, services, and supplies, including due to geopolitical instability or sanctions.
• Fluctuations in foreign currency exchange rates.
• Evolving changes in environmental, health, and safety regulations or preferences, and general economic, social, and business conditions.
• Health and safety risks associated with the use, storage, transportation, and disposal of potentially hazardous materials such as EO and Co-60.
• Impact and outcome of current and future legal proceedings and liability claims, including litigation related to EO emissions and releases from facilities in California, Georgia, Illinois, and New Mexico, and the possibility of additional claims.
• Ability to satisfy conditions for settlement of EO claims related to the former Willowbrook, Illinois facility.
• Allegations of failure to properly perform services and potential product liability claims, recalls, penalties, and reputational harm.
• Compliance with extensive regulatory requirements, related costs, and failures or delays in receiving required clearances or approvals.
• Adverse changes in industry trends and competition.
• Market conditions and changes, including inflationary trends and tariffs, impacting long-term supply contracts with variable price clauses and increasing cost of revenues.
• Business continuity hazards, including supply chain disruptions.
• Risks of doing business internationally, including global/regional economic/political instability and compliance with inconsistent laws/regulations.
• Ability to increase capacity at existing facilities, build new facilities timely and cost-effectively, and renew leases.
• Ability to attract and retain qualified employees.
• Severe health events or environmental events.
• Cybersecurity incidents, unauthorized data disclosures, and dependence on information technology systems.
• Inability to pursue strategic transactions, find suitable acquisition targets, or integrate acquisitions successfully.
• Ability to maintain effective internal control over financial reporting.
• Reliance on intellectual property and risk of infringement claims.
• Ability to comply with rapidly evolving data privacy and security laws and regulations.
• Ability to generate profitability in future periods.
• Impairment charges on goodwill and other intangible assets.
• Effects of unionization efforts and labor regulations.
• Adverse changes to tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of operations.
• Significant leverage and how this significant leverage could adversely affect ability to raise additional capital, limit ability to react to challenges confronting the Company or broader changes in the industry or the economy, limit flexibility in operating the business through restrictions contained in debt agreements and/or prevent meeting obligations under existing and future agreements governing indebtedness.

Future Outlook

The company expects cash on hand, operating cash flows, and available credit facilities to provide sufficient working capital for operations, debt service, capital expenditures, and litigation costs for at least the next twelve months and the foreseeable future. Long-term liquidity requirements include debt service, capital expenditures, and potential business acquisitions. The company is evaluating the impact of the new 'One Big Beautiful Bill Act' tax legislation but does not expect a material impact on its results of operations.

Management Comments

• We are driven by our mission: Safeguarding Global Health.
• We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world.
• Our services are an essential aspect of our customers manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients.
• Most of these services are necessary for our customers to satisfy applicable government requirements.
• We serve our customers throughout their product lifecycles, from product design to manufacturing and delivery, helping to ensure the sterility, effectiveness and safety of their products for the end user.
• The combination of Sterigenics, our terminal sterilization business, and Nordion, our Co-60 supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry. This provides us with additional insights and allows us to better serve our customers.
• Based on our view of the strength of the science and related evidence that emissions of EO from Sterigenics operations have not caused and could not have caused the harms alleged in such lawsuits, we believe that losses in the remaining or future EO cases through trials and any appeals that may prove necessary are not probable.
• Although the Company is vigorously defending against the EO tort claims, future settlements of EO tort claims are reasonably possible.
• The previously disclosed settlements of certain cases related to our facilities in Willowbrook and Atlanta and the resolution of the tort lawsuit pending in the United States District Court for the District of New Mexico... were driven by dynamics unique to the claims that were settled and thus should not give rise to presumptions that the Company will settle additional EO tort claims and/or that any such settlements will be for comparable amounts.
• Potential trial and settlement outcomes can vary widely based on a host of factors.
• The outcomes of trials before juries are rarely certain and a judgment rendered or settlement reached in one case is not necessarily representative of potential outcomes of other seemingly comparable cases.
• As a result, it is not possible to estimate a reasonably possible loss or range of loss with respect to any future EO tort lawsuit, trial or settlement.

Industry Context

Sotera Health operates as a leading global provider of mission-critical sterilization and lab testing services for the healthcare industry, positioning itself as an essential partner in medical, pharmaceutical, and food product safety. Its unique vertical integration of Sterigenics (terminal sterilization) and Nordion (Cobalt-60 supply) differentiates it in the gamma sterilization market. The ongoing Ethylene Oxide (EO) litigation, while specific to Sotera, highlights broader environmental and regulatory scrutiny faced by companies handling hazardous materials in the sterilization sector. The company's focus on core lab testing growth in Nelson Labs, despite a decline in expert advisory services, reflects a strategic emphasis on its foundational offerings within the competitive lab services market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.
• The company highlights its unique position as the only vertically integrated global gamma sterilization provider, combining Sterigenics and Nordion, which suggests a competitive advantage in this niche.
• The ongoing EO litigation, while a significant financial burden, is noted as comparable to threats made against 'other companies within our industry,' implying that such legal challenges are an industry-wide concern rather than unique to Sotera Health.

Legal Proceedings

• **Ethylene Oxide (EO) Tort Litigation**:
• **California (Vernon Cases)**: Seven lawsuits in Los Angeles County Superior Court with approximately 80 claims for personal injury or wrongful death allegedly from EO emissions. Discovery is underway.
• **Georgia (Atlanta Cases)**: Approximately 380 personal injury and wrongful death claims consolidated for pretrial purposes in the State Court of Cobb County. A Phase 1 ruling on general causation was issued on November 22, 2024, and is currently under appeal. Phase 2 discovery closed in June 2025, with motions to exclude experts and for summary judgment pending. Trial for the first pool case is scheduled for March 16, 2026. Additionally, one personal injury lawsuit is stayed, and approximately 340 property devaluation lawsuits are consolidated, with nine in discovery and the rest stayed. One lawsuit from customer employees alleging injury from residual EO is ongoing, with the customer indemnifying Sterigenics.
• **Illinois (Willowbrook Cases)**: On April 3, 2025, a binding term sheet was entered to resolve 97 pending and threatened EO claims for $30.9 million, with 100% participation by Eligible April Claimants by June 28, 2025. On July 23, 2025, a binding term sheet was entered to resolve 129 pending and threatened EO claims for $34.0 million, subject to 100% participation and a good faith determination. If finalized, only one Willowbrook case will remain pending.
• **New Mexico**: A lawsuit by the New Mexico Attorney General alleges air quality deterioration and increased health risks from EO emissions. The Court of Appeals denied an interlocutory appeal of a summary judgment order, and a motion to reinstate healthcare cost damages is pending. Trial is set for July 2026.
• The company believes losses in remaining or future EO cases are not probable based on scientific evidence but acknowledges future settlements are reasonably possible.
• **Insurance Coverage for Environmental Liabilities**: An existing environmental liability insurance policy ($10 million per occurrence, $20 million aggregate) has been fully utilized for defense costs in Georgia, Illinois, and New Mexico litigation. Future insurance policies exclude coverage for EO claims. The company is pursuing additional insurance coverage for legal expenses related to EO tort lawsuits. In the Northern District of Illinois Coverage Lawsuit, a judgment of $110.2 million for defense costs was secured in January 2024, which is currently under appeal. The Seventh Circuit Court of Appeals certified a question of Illinois law to the Illinois Supreme Court on April 11, 2025. Other insurance coverage lawsuits in Cook County, Delaware, and Los Angeles County Superior Courts are stayed pending the Illinois Supreme Court's resolution of the certified question.
• **Sotera Health Company Securities Litigation and Related Matters**: The Michigan Funds Litigation (stockholder class action) was dismissed with prejudice on March 19, 2025, but the plaintiffs have appealed to the Sixth Circuit. The May 2024 Derivative Litigation (stockholder derivative lawsuit) was stayed on June 25, 2024, pending a ruling on the Michigan Funds Litigation. The company has received and is responding to demands for inspection of books and records (220 Demands) from shareholders investigating potential wrongdoing related to EO safety statements.

Stakeholder Impact

• **Shareholders**: Impacted by the net loss for the six-month period due to litigation settlements, but also by positive Adjusted EBITDA growth. Ongoing legal proceedings and appeals create uncertainty regarding future financial performance and potential liabilities.
• **Customers**: Continued access to mission-critical sterilization and lab testing services. Nordion's sales patterns can vary, impacting supply.
• **Employees**: Share-based compensation plans are in place. No specific impact mentioned beyond general business operations.
• **Creditors**: The company remains in compliance with all debt covenants, and liquidity is strong with increased cash and available credit, indicating ability to service debt.
• **Communities near EO facilities**: Ongoing legal proceedings in California, Georgia, Illinois, and New Mexico highlight community concerns regarding EO emissions and potential health risks. Settlements in Illinois aim to resolve some claims.

Next Steps

• Trial of the first pool case in Georgia EO litigation is scheduled to begin on March 16, 2026.
• Motions to exclude certain expert witnesses and for summary judgment in Georgia EO litigation remain pending.
• The New Mexico Attorney General's motion to reinstate healthcare cost damages claim remains pending, with trial set for July 2026.
• Appeals are pending before the Georgia Court of Appeals regarding the Phase 1 ruling on general causation issues in the Atlanta Cases.
• The Michigan Funds have appealed the dismissal of the stockholder class action to the United States Court of Appeals for the Sixth Circuit.
• The May 2024 Derivative Litigation is stayed pending the ruling on the merits of the Michigan Funds Litigation.
• The company is pursuing additional insurance coverage for legal expenses related to EO tort lawsuits.
• The Illinois Supreme Court is pending a certified question of Illinois law regarding insurance coverage.
• The company will continue to evaluate the impact of the new U.S. tax legislation ('One Big Beautiful Bill Act' or 'OBBBA').
• The company expects to reclassify approximately $0.4 million of pre-tax net gains on derivative instruments from accumulated other comprehensive income (loss) to income during the next 12 months.

Key Dates

Recommendation

While Sotera Health demonstrates robust operational performance with strong revenue growth and increased Adjusted EBITDA across its segments, the significant financial impact of Ethylene Oxide (EO) litigation settlements has led to a GAAP net loss for the first half of 2025. The ongoing legal uncertainties, including appeals and pending trials in multiple states, represent a material overhang on the company's financial outlook and could lead to further substantial costs. The company's strong liquidity and compliance with debt covenants provide stability, but the persistent legal risks warrant a cautious 'Hold' recommendation for investors until there is greater clarity on the ultimate resolution and financial impact of the EO litigation.

Keywords

Sterilization Services, Lab Testing, Ethylene Oxide, Cobalt-60, Medical Device Sterilization, Pharmaceutical Testing, Healthcare Industry, Regulatory Compliance, Environmental Litigation, SEC Filing, Quarterly Report, Sotera Health